What the Clinic Never Checked
A 47-year-old with a year of unmonitored compounded testosterone from a direct-to-consumer clinic and an incidentally elevated hematocrit — testing what an honest re-entry into the regulated system actually looks like.
Roland F. runs his own HVAC repair business and responded to a targeted online advertisement for a low-testosterone clinic fourteen months ago after several months of fatigue, weight gain, and low libido he attributed, reasonably enough at first, to the stress of running a small business alone. The clinic, which he now describes candidly as having asked few questions and ordered minimal testing, started him on a compounded testosterone cream after a single non-fasting testosterone level and no assessment of his pituitary function, PSA, or baseline hematocrit. He has been using it since without any follow-up bloodwork, until his new primary care physician, seeing him for an unrelated concern, ordered a panel that came back with a hematocrit of 56%.
Compounded hormone products occupy a real regulatory gray zone: pharmacy compounding itself is legal and serves genuine clinical needs, but compounded testosterone specifically is not FDA-approved, meaning its dosing consistency, actual concentration, and purity are not verified the way a manufactured product's are, and prescribing clinics operating primarily through direct-to-consumer advertising have drawn specific regulatory and professional-society concern for exactly the pattern Roland describes: minimal diagnostic rigor at initiation and little to no ongoing monitoring once treatment starts. Nissen, one of TRAVERSE's own principal investigators, made this point directly in discussing that trial's findings: TRAVERSE's reassuring safety data was generated in a carefully monitored, protocol-driven population, and its results don't automatically extend to men obtaining testosterone entirely outside those parameters — exactly Roland's situation for the past fourteen months.
His hematocrit of 56% is a real, immediate safety finding requiring attention on its own, independent of the compounding-versus-regulated-product question, and sits above even the more permissive thresholds used in the erythrocytosis literature. But the more complete failure sitting underneath that one lab value is the total absence of monitoring around it: no PSA has ever been checked, no baseline pituitary function was assessed before treatment started, and no one has confirmed, on properly drawn morning labs, that Roland was ever truly hypogonadal to begin with, as opposed to responding to a single, non-standardized test result at a clinic with a financial interest in a positive diagnosis.
New-patient visit, closing a monitoring gap without scolding the patient
A hematocrit of 56% is a real, immediate safety finding on its own, above even the more permissive thresholds in the literature, and it's sitting on top of fourteen months with no PSA ever checked and no confirmed baseline diagnosis at all. Whatever brought him to that clinic, the monitoring gap in front of us right now needs closing before anything else — full re-workup, starting today.
I agree the gap needs closing, and I don't want anything I say to slow that down. But I think it's worth naming honestly why men like Roland end up at these clinics in the first place, because if we don't address that part too, he goes right back to the same unregulated source once this visit is over. A lot of symptomatic, genuinely suffering men don't cleanly meet the strict biochemical criteria insurance often requires for coverage of regulated testosterone therapy, and a rushed primary care visit isn't always set up to properly investigate hypogonadal symptoms the way this workup deserves.
This isn't an argument against the re-workup — it's an argument for making sure the regulated path we're offering him actually works logistically, or he has a real reason to go back to the version that didn't ask him for much.
Then the plan should do both at once: formal re-workup today, confirmed AM fasting testosterone, LH, FSH, PSA, and a repeat hematocrit, alongside a direct conversation about what regulated, monitored therapy actually requires and a specific plan for what happens if his insurance doesn't cover it cleanly — rather than leaving him with a stopped prescription and no real path forward once he walks out of here.
Agreed: compounded testosterone stopped today pending a full, properly standardized re-workup, with an explicit conversation about transitioning to an FDA-approved, monitored regimen once his diagnosis is confirmed, and a specific discussion of what to do if insurance coverage proves to be a real barrier rather than leaving that question for a future visit.
The endocrinologist's point about the access pressures underlying his original decision was not treated as an excuse to delay closing the safety gap, but it did shape how the conversation with Roland went — explaining the re-workup as a path back into a system that will actually monitor him, not simply as a correction of something he did wrong.